Arul Prakash Francis
Overview
Explore the profile of Arul Prakash Francis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
184
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Manivannan H, Veeraraghavan V, Francis A
Appl Biochem Biotechnol
. 2025 Jan;
PMID: 39820926
The primary objective of this study was to identify bioactive compounds from four medicinal plants with multi-targeting activity against hepatocellular carcinoma (HCC). A comprehensive analysis led to the identification of...
2.
Rajkumar C, Ramsridhar S, Veeraraghavan V, Francis A, Purushotham M, Mageshwari U
Discov Oncol
. 2024 Nov;
15(1):688.
PMID: 39570553
Background And Objective: Oral squamous cell carcinoma is the most common form of mouth cancer. As plant-based medicines become increasingly popular, Moringa oleifera has been studied extensively for its plant-based...
3.
Unnikrishnan Meenakshi D, Narde G, Ahuja A, Al Balushi K, Francis A, Khan S
Pharmaceutics
. 2024 Jun;
16(6).
PMID: 38931884
Natural compounds such as polyphenols play several positive roles in maintaining the oxidative and inflammatory capacity of cells, which leads to their potential use as anticancer therapeutics. There is promising...
4.
Kumar U, Manivannan H, Francis A, Veeraraghavan V, R G, Sankaran K
Cureus
. 2024 Jan;
15(12):e50863.
PMID: 38259388
Introduction Cancer continues to pose a significant challenge in medical research. Phytochemicals derived from plants have emerged as a promising avenue for pioneering drug discovery due to their potential for...
5.
Manivannan H, Veeraraghavan V, Francis A
Curr Comput Aided Drug Des
. 2024 Jan;
PMID: 38231067
Background: Triple-negative breast cancer (TNBC) is a highly aggressive form of breast cancer lacking specific receptors, with dysregulated and overactivated Hedgehog (Hh) and mTOR/PI3K/AKT signaling pathways as potential therapeutic targets....
6.
Manivannan H, Veeraraghavan V, Francis A
Mol Divers
. 2023 Dec;
28(6):3835-3857.
PMID: 38145425
Breast cancer, a highly prevalent and fatal cancer that affects the female population worldwide, stands as a significant health challenge. Despite the abundance of chemotherapy drugs, the adverse side effects...
7.
Venkateswaran S, Manivannan H, Francis A, Veeraraghavan V, R G, Sankaran K
Cureus
. 2023 Nov;
15(10):e48000.
PMID: 38034159
Background Metastatic colorectal cancer (mCRC) continues to rank as the second deadliest cancer on the global scale. CRC diagnosed at metastatic (stage IV) makes treatment strategies more challenging. Even though...
8.
A S S, Biju T, Francis A, R G, Veeraraghavan V, Sankaran K
Cureus
. 2023 Sep;
15(8):e44209.
PMID: 37767269
Introduction: Oral inflammation, often triggered by infections, injuries, or immune responses, can compromise treatment outcomes, delay healing, and contribute to patient discomfort. The development of green nanoparticle synthesis methods is...
9.
Francis A, Unnikrishnan Meenakshi D, Ganapathy S, Devasena T
Environ Sci Pollut Res Int
. 2023 Sep;
31(34):46641-46651.
PMID: 37710065
Carbon nanotubes (CNTs) exposure in human beings through inhalation may affect pulmonary organs and extrapulmonary organs including liver, kidney, brain, spleen, etc. The toxic effects developed as the result of...
10.
Francis A, Ahmad A, Nagarajan S, Yogeeswarakannan H, Sekar K, Khan S, et al.
Pharmaceutics
. 2023 Jul;
15(7).
PMID: 37514105
Acyclovir (ACV) is a promising candidate for drug repurposing because of its potential to provide an effective treatment for viral infections and non-viral diseases, such as cancer, for which limited...